An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States-Reference-Cited by-同舟云学术

An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States

Published:2023-12-19 Issue:1 Volume:27 Page:77-83
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Oluwole Olalekan O.¹^ORCID,Patel Anik R.²,Vadgama Sachin²,Smith Nathaniel J.³,Blissett Rob³,Feng Chaoling²,Dickinson Michael⁴,Johnston Patrick B.⁵,Perales Miguel-Angel⁶⁷^ORCID

Affiliation:

1. Vanderbilt University Medical Centre, Nashville, TN, USA

2. Kite, a Gilead company, Santa Monica, CA, USA

3. Maple Health Group, New York, NY, USA

4. Peter MacCallum Cancer Centre, Melbourne, Australia

5. Mayo Clinic, Rochester, MN, USA

6. Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

7. Department of Medicine, Weill Cornell Medical College, New York, NY, USA

Funder

Gilead Sciences

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2023.2290832

Reference32 articles.

1. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

2. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

3. The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial

4. Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma

5. Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medicare Utilization and Cost Trends for CAR T Cell Therapies Across Settings of Care in the Treatment of Diffuse Large B-Cell Lymphoma;Advances in Therapy;2024-06-25

2. Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States;Journal of Medical Economics;2024-06-06

3. Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre‐autologous stem cell transplant in relapsed/refractory diffuse large B‐cell lymphoma—outcome of rituximab‐dose‐intensive cyclophosphamide, etoposide, cisplatin (R‐DICEP) versus R‐GDP;British Journal of Haematology;2024-05-27